U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H29NO3
Molecular Weight 379.492
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DONEPEZIL

SMILES

COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1

InChI

InChIKey=ADEBPBSSDYVVLD-UHFFFAOYSA-N
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C24H29NO3
Molecular Weight 379.492
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Aricept is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer’s Disease, as well as in patients with severe Alzheimer’s Disease. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.

CNS Activity

Originator

Approval Year

1996
224
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 6.7 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
ARICEPT

Approved Use

Donepezil hydrochloride orally disintegrating tablets, USP are an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease (1). Donepezil hydrochloride orally disintegrating tablets, USP are indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
34.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
60.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2889.3 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5051.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
72.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
73.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
175 mg single, transdermal
Dose: 175 mg
Route: transdermal
Route: single
Dose: 175 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
healthy, 24.9±3.3 years
Health Status: healthy
Age Group: 24.9±3.3 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
175 mg 1 times / 3 days steady, transdermal
Dose: 175 mg, 1 times / 3 days
Route: transdermal
Route: steady
Dose: 175 mg, 1 times / 3 days
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
healthy, 24.9±3.3 years
Health Status: healthy
Age Group: 24.9±3.3 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Disc. AE: Bradycardia, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Bradycardia (0.7%)
Diarrhea (1.7%)
Nausea (1.9%)
Vomiting (2.9%)
QT interval prolonged (0.4%)
Anorexia (0.3%)
Dizziness (1.1%)
Headache (0.4%)
Somnolence (0.6%)
Syncope (0.2%)
Aggression (0.5%)
Agitation (0.8%)
Confusional state (0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
Health Status: unhealthy
Age Group: 79 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (1 patient)
Vomiting (1 patient)
Bradycardia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
unhealthy, 80 years
Health Status: unhealthy
Age Group: 80 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
Disc. AE: Myoclonus...
AEs leading to
discontinuation/dose reduction:
Myoclonus (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (3%)
Nausea (3%)
Vomiting (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (<1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Syncope 0.2%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Anorexia 0.3%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Headache 0.4%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
QT interval prolonged 0.4%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Aggression 0.5%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Somnolence 0.6%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Bradycardia 0.7%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Confusional state 0.7%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Agitation 0.8%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Dizziness 1.1%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Diarrhea 1.7%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Nausea 1.9%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Vomiting 2.9%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
unhealthy, 73.9 years
Health Status: unhealthy
Age Group: 73.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Bradycardia 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
Health Status: unhealthy
Age Group: 79 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Nausea 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
Health Status: unhealthy
Age Group: 79 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Vomiting 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
Health Status: unhealthy
Age Group: 79 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Myoclonus 1 patient
Disc. AE
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
unhealthy, 80 years
Health Status: unhealthy
Age Group: 80 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
Vomiting 2%
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Diarrhea 3%
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Nausea 3%
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Diarrhea <1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:53289
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:53289
ChemicalBook
CB0156314
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0156314
ChemicalBook
CB23334700
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB23334700
ChemicalBook
CB62741796
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB62741796
ChemicalBook
CB73050236
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB73050236
eMolecules
873089
https://www.emolecules.com/cgi-bin/more?vid=873089
MolPort
MolPort-003-847-014
https://www.molport.com/shop/molecule-link/MolPort-003-847-014
PubMed

PubMed

TitleDatePubMed
Donepezil management of schizophrenia with associated dementia.
2002-04
In vitro toxicity of rivastigmine and donepezil in cells of epithelial origin.
2002-03-27
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
2002-03-12
How many patients complete an adequate trial of donepezil?
2002-03-08
[Risperidone in the ambulatory treatment of behavior disorders in demented patients of Alzheimer's type: a retrospective analysis].
2002-03-07
Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection.
2002-03-05
Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease.
2002-03-05
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.
2002-03-01
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
2002-03
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
2002-03
Therapeutic effects of an acetylcholinesterase inhibitor (donepezil) on memory in Wernicke-Korsakoff's disease.
2002-02-20
Lewy body dementia: case report and discussion.
2002-02-14
Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
2002-02-08
Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety.
2002-02
Feasibility of vascular dementia treatment with cholinesterase inhibitors.
2002-02
[Alzheimer dementia. Intervening as early as possible].
2002-01-17
A new HPLC method to determine Donepezil hydrochloride in tablets.
2002-01-01
[Pharmacotherapy for the treatment of Alzheimer's disease--the present state and the development in the future].
2002-01
Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
2002
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
2001-12-13
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
2001-12
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
2001-12
Unsafe prescription medication switching recommendations.
2001-12
Donepezil in schizophrenia--is it helpful? An experimental design case study.
2001-12
Alzheimer's disease: recent advances in etiology, diagnosis, and management.
2001-12
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
2001-11-29
SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals.
2001-11-16
A case of Korsakoff's syndrome improved by high doses of donepezil.
2001-11-13
Equity in the new NHS. Evidence cannot help in all situations.
2001-11-10
Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil.
2001-11-08
Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat.
2001-11
[Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies].
2001-11
Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
2001-11
Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target.
2001-11
[Relief for caregivers. Anti-dementia drug saves costs].
2001-10-18
Treatment of tardive dyskinesia with donepezil: a pilot study.
2001-10
[Effectiveness of donepezil on several cognitive functions in patients with Alzheimer's disease over 12 months].
2001-10
Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease.
2001-10
[Anticholinesterase agents in Alzheimer's disease].
2001-09
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
2001-08-28
Maintaining functional and behavioral abilities in Alzheimer disease.
2001-08
Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
2001-08
[A patient with probable dementia with Lewy bodies, who showed improvement of dementia and parkinsonism by the administratim of donepezil].
2001-07
Featured CME topic: dementia. Medication update.
2001-07
Donepezil hydrochloride: a treatment drug for Alzheimer's disease.
2001
Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
2001
Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.
2001
The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia.
2001
EEG changes during long-term treatment with donepezil in Alzheimer's disease patients.
2001
Galantamine for Alzheimer's disease.
2001
Patents

Patents

08318942
5
08552195
4
20010039275
12
JP2004131469A
4
JP2007091685A
4
JP2007512338A
11
JP2008195714A
4
JP2011246491A
4
JPH11106353A
4

Sample Use Guides

In Vivo Use Guide
Mild to Moderate Alzheimer’s Disease - 5 mg or 10 mg administered once daily Moderate to Severe Alzheim er’s Disease - 10 mg or 23 mg administered once daily A dose of 10 mg once daily can be administered once patients have been on a daily dose of 5 mg for 4 to 6 weeks. A dose of 23 mg once daily can be administered once patien ts have been on a dose of 10 mg once daily for at least 3 months
Route of Administration: Oral
In Vitro Use Guide
Donepezil inhibited freshly prepared human erythrocyte AChE with IC50 22 nM
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:23:23 GMT 2025
Edited
by admin
on Mon Mar 31 18:23:23 GMT 2025
Record UNII
8SSC91326P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DONEPEZIL
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
DONAZ
Preferred Name English
D-797
Common Name English
1-BENZYL-4-((5,6-DIMETHOXY-1-INDANON-2-YL)METHYL)PIPERIDINE
Systematic Name English
5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-2,3-DIHYDRO-1H-INDEN-1-ONE
Systematic Name English
Donepezil [WHO-DD]
Common Name English
DONEPEZIL [JAN]
Common Name English
donepezil [INN]
Common Name English
(±)-2-((1-BENZYL-4-PIPERIDYL)METHYL)-5,6-DIMETHOXY-1-INDANONE
Systematic Name English
1H-INDEN-1-ONE, 2,3-DIHYDRO-5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-
Systematic Name English
DONEPEZIL [HSDB]
Common Name English
DONEPEZIL [VANDF]
Common Name English
2,3-DIHYDRO-5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-1H-INDEN-1-ONE
Systematic Name English
D797
Common Name English
DONEPEZIL [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175723
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
WHO-VATC QN06DA02
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
NDF-RT N0000000177
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
WHO-VATC QN06DA52
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
WHO-ATC N06DA52
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
LIVERTOX NBK548197
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
WHO-ATC N06DA53
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
WHO-ATC N06DA02
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
NCI_THESAURUS C47792
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
Code System Code Type Description
RXCUI
135447
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY RxNorm
CAS
120014-06-4
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
FDA UNII
8SSC91326P
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
DAILYMED
8SSC91326P
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
WIKIPEDIA
DONEPEZIL
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
CHEBI
53289
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
MESH
C076946
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
MERCK INDEX
m4738
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY Merck Index
INN
7517
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
DRUG CENTRAL
946
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
SMS_ID
100000080761
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
DRUG BANK
DB00843
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
IUPHAR
6599
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
HSDB
7743
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL502
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
EVMPD
SUB06362MIG
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
NCI_THESAURUS
C66874
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
EPA CompTox
DTXSID8048317
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
PUBCHEM
3152
Created by admin on Mon Mar 31 18:23:23 GMT 2025 , Edited by admin on Mon Mar 31 18:23:23 GMT 2025
PRIMARY
Related Record Type Details
Structure of DONEPEZIL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of DONEPEZIL OXALATE
SALT/SOLVATE -> PARENT
ACETYLCHOLINESTERASE HUMAN
TARGET -> INHIBITOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
DONEPEZIL N-OXIDE
METABOLITE -> PARENT
Structure of 5-O-DESMETHYLDONEPEZIL GLUCURONIDE
METABOLITE -> PARENT
Structure of DONEPEZIL N-OXIDE, TRANS-
METABOLITE -> PARENT
Structure of 5-O-DESMETHYL DONEPEZIL
METABOLITE -> PARENT
Structure of 6-O-DESMETHYLDONEPEZIL GLUCURONIDE
METABOLITE -> PARENT
Structure of 6-O-DESMETHYLDONEPEZIL
METABOLITE -> PARENT
Structure of DESBENZYL DONEPEZIL
METABOLITE -> PARENT
Structure of DONEPEZIL N-OXIDE, CIS-
METABOLITE -> PARENT
Related Record Type Details
Structure of 3-HYDROXYDONEPEZIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DONEPEZIL OPEN-RING KETO ACID
IMPURITY -> PARENT
Related Record Type Details
Structure of DONEPEZIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966